a

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem nulla consequat. Aenean massa.

EVENTS & NEWS

RCMO POST COVID -19 INFORMATION

Malaysia has entered the recovery phase of control movement order (RCMO) starting from 10th June 2020 till 31st August 2020 hoping to further bring down the infection figure. At the current stage, many restrictions have been loosened by the government to boost economic growth. In echo to the RCMO, UMMC […]

SELAMAT HARI RAYA AIDILFITRI FROM CIC

Greeting from Clinical Investigation Centre (CIC), We would like to take this opportunity to thank you for your kind support to CIC all this while. Wishing everyone 'Selamat Hari Raya Aidilfitri & Maaf Zahir Batin! and Happy Holiday!'

CLINICAL TRIALS FACTSHEET ON COVID-19 WORLDWIDE BY DR. PHAN CHIA WEI, HEAD OF CIC

Factsheet written by Dr Phan Chia Wei, Head of CIC, on clinical trials on COVID-19 worldwide. The factsheet is published by the Academy of Science Malaysia (ASM) in collaboration with the Young Scientists Network (YSN). To add, we would like to express our heartiest congratulations to a new clinical trial […]

Happy Ramadhan Kareem

Ahlan Wa Sahlan Ya Ramadhan. Wishing everyone a Blessed Ramadhan Kareem. More

UM LEADS CLINICAL TRIALS FOR TOCILIZUMAB IN COVID-19 TREATMENT

Malaysia is embarking on a clinical study to evaluate the drug Tocilizumab for the treatment of severe cases of Covid-19. Led by Universiti Malaya Faculty of Medicine dean Professor Datuk Dr Adeeba Kamarulzaman, the trial is underway at Universiti Malaya Medical Centre (UMMC), together with three public hospitals: Sungai Buloh […]

UMMC, MOH HOSPITALS STUDYING ARTHRITIS DRUG TREATMENT FOR SEVERE COVID-19

Great news and new hope! CIC and the UMMC Covid-19 special taskforce go full force looking for new treatment for Covid-19 patients. “UMMC has already used tocilizumab (trade name Actemra) on several Covid-19 patients who developed “cytokine storm” syndrome, a dangerous overreaction of the immune system, resulting in respiratory and […]

ARE YOU INTERESTED?

Study Name
Indication/Details
Eligibility
Study Status
Register Interest
P1-PKPD-Metabolomics
  • Males
  • Aged 18 – 45 years old
  • Body Mass Index (BMI) 18 - 25kg/m²[min 50kg]
  • Non-smokers and healthy
  • Legible(able to read English or Malay)
Currently Recruiting

FAQ

Know you answer from your questions

ELECTRONIC MEDICAL RECORD (EMR)
FLOWCHART ON HOW TO CONDUCT CLINICAL TRIAL THROUGH CIC

GUIDELINE FOR APPLYING MEDICAL ETHICS COMITTEE

PHASES OF CLINICAL TRIALS (PHASE I, II, III, IV)

PHASE I
Phase 1 studies are usually conducted in healthy volunteers. The goal here is to determine what the drug’s most frequent side effects are and, often, how the drug is metabolized and excreted. The number of subjects typically ranges from 20 to 80..

PHASE II
Phase 2 studies begin if Phase 1 studies don’t reveal unacceptable toxicity. While the emphasis in Phase 1 is on safety, the emphasis in Phase 2 is on effectiveness. This phase aims to obtain preliminary data on whether the drug works in people who have a certain disease or condition. For controlled trials, patients receiving the drug are compared with similar patients receiving a different treatment–usually an inactive substance (placebo), or a different drug. Safety continues to be evaluated, and short-term side effects are studied. Typically, the number of subjects in Phase 2 studies ranges from a few dozen to about 300

PHASE III
Phase 3 studies begin if evidence of effectiveness is shown in Phase 2. These studies gather more information about safety and effectiveness, studying different populations and different dosages and using the drug in combination with other drugs. The number of subjects usually ranges from several hundred to about 3,000 people.

PHASE IV
Phase IV trials gather more information about the possible risks and benefits of a drug that didn’t show up in earlier testing. Researchers look into risks and benefits that could be associated with long-term effects after a drug or treatment has been approved for clinical use. In this phase, researchers continue to follow participants who have completed phase III trials. Not all new treatments will enter into phase IV studies

IF YOU HAVE ANY QUERIES REGARDING THE BELOW ITEMS, KINDLY CONTACT
I-RESEARCH APPLICATION

Mr. Banusanthar Lohanathan(Science Officer)
Contact No: 03-7949 2351
Email: banusanthar@ummc.edu.my

 

Ms. Khairulbariah Baharum(IT Officer)
Contact No: 03-7949 2351
Email: khairulbariah@ummc.edu.my

 

FINANCIAL MATTERS

Ms. Noor Aziza Ismail @ Aziz(Accountant)
Contact No : 03 7949 2886
Email: aziza.ismail@ummc.edu.my

 

Mdm. Nur Fathin Maisarah Azami (Account Assistant)
Contact No : 03 7949 2886
Email: fathinm@ummc.edu.my

 

Mdm. Nur ‘Ain Haris (Account Assistant)
Contact No : 03 7949 2886
Email: nurain.haris@ummc.edu.my

 

LEGAL MATTERS

(CLINICAL TRIAL AGREEMENT)
Ms. Nurul Najihah Saupi (Legal Officer)
Contact No : 03 7949 2886
Email:  najihah.saupi@ummc.edu.my

 

Ms. Nahra Yasmin Anuar (Legal Officer)
Contact No : 03 7949 2886
Email:  nahra.anuar@ummc.edu.my

 

BUDGET NEGOTIATION

Ms. Juliana Wang Piek Lian (Science Officer)
Contact No : 03 7949 2886
Email: wangpl@ummc.edu.my

 

Ms. Nurbazlin Musa (Science Officer)
Contact No : 03 7949 2886
Email: nurbazlin@ummc.edu.my

 

Mdm. Nurul Zfarina Mohd Zaid (Assistant Science Officer)
Contact No : 03 7949 2886
Email: nurulzfarina.zaid@um.edu.my

 

TRAINING AND FACILITIES

Mdm. Nur Hidayah Zakaria (Medical Lab Technologist)
Contact No: 03-7949 2351
Email: hiedayah@um.edu.my

 

Ms. Hanis Hafizah Ismail(Science Officer)
Contact No: 03-7949 2351
Email: hanishafizah@ummc.edu.my